How should biotech and pharma teams implement segmentation after assuming breach?

Biotech and pharma teams should start by identifying their crown jewels, then map the devices, users, and business processes that legitimately need access to them. From there, they can layer IAM, vulnerability management, and segmentation so critical applications are reachable only from authorised devices and only for approved functions. The goal is not perfect prevention, but limiting blast radius when an intruder gets inside.

How to segment biotech and pharma environments after breach assumptions

Segmentation works best when it is designed around what must still function during compromise, not around an idealised perimeter. In biotech and pharma, that usually means separating research, manufacturing, lab instrumentation, quality, and business systems so access paths are narrow, inspectable, and tied to specific business functions. The practical goal is to preserve essential operations while preventing one foothold from becoming enterprise-wide impact.

What to segment first in biotech and pharma

Start with the assets and workflows whose compromise would be most damaging: crown-jewel data, regulated manufacturing systems, lab systems, shared identity services, and any platform that can move from IT into OT or regulated environments. Then identify the minimum number of users, devices, service accounts, and integrations that legitimately need access. That inventory is what makes segmentation enforceable rather than symbolic.

In this sector, segmentation is rarely just about network ranges. It also needs to reflect application boundaries, device trust, remote access paths, and data movement rules. If a sequencing environment, manufacturing line, or formulation system can be reached from ordinary office endpoints, the design is too permissive even if the VLANs look tidy on paper.

For teams that want a more formal blueprint, NIST’s Zero Trust Architecture is a strong fit because it treats trust as something to verify continuously, not something to inherit from network location.

How to make segmentation survive real intrusions

Once the trust zones are clear, enforce them with multiple control layers. IAM should decide who or what may enter each zone, vulnerability management should reduce the chance that a reachable system becomes the next pivot point, and segmentation should limit east-west movement if an attacker or malware lands inside. The point is to keep the blast radius small even when authentication or endpoint security fails somewhere upstream.

In practice, that means separating administration paths from user paths, separating human access from service access, and preventing broad shared credentials from becoming a universal bridge. Critical applications should be reachable only from approved devices and only for approved functions, with exceptions treated as temporary and well-documented rather than normal operating conditions.

OT-adjacent biotech and pharmaceutical operations need extra care because lab and production environments often have longer lifecycles, more vendor dependencies, and less tolerance for disruptive patching. NIST’s OT Security Guide is useful here because it treats segmentation as part of preserving process safety and operational continuity, not just reducing IT exposure.

Where segmentation usually fails in biotech and pharma

The most common failure is assuming a flat environment is acceptable because access is “controlled” at the front door. In reality, once an intruder has a foothold, flat connectivity turns ordinary trust relationships into lateral movement paths. Shared service accounts, overly broad remote support, and legacy lab or plant connections often become the shortest route from a low-value workstation to a high-value production or research system.

Another common issue is segmentation that looks strong in diagrams but is weak in exception handling. Temporary firewall rules, vendor tunnels, and emergency admin paths tend to accumulate, and each exception quietly erodes the intended isolation. If those exceptions are not reviewed and removed, segmentation becomes a paper control rather than a containment control.

The breach lesson is simple: containment only works when the boundaries are narrower than the attacker’s practical pivot options. NHIMG’s The 52 NHI Breaches Report illustrates how stolen credentials, service accounts, and lateral movement can turn an initial intrusion into broader compromise when access paths are too permissive.

Standards & Framework Alignment

This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.

OWASP Non-Human Identity Top 10 addresses the attack surface, NIST Zero Trust (SP 800-207), NIST SP 800-53 Rev 5 and CIS Controls v8 set the technical controls, and ISO/IEC 27001:2022 defines the regulatory obligations.

Framework	Control / Reference	Relevance
NIST Zero Trust (SP 800-207)	PR.AA-05 — Least Privilege	Segmentation after breach assumptions depends on verifying and limiting access by trust context.
Recommendation — Apply least-privilege access and continuous verification at each segment boundary.
NIST SP 800-53 Rev 5	AC-4 — Information Flow Enforcement	Directly governs restricting flows between biotech and pharma trust zones.
	IA-9 — Identification and Authentication (Non-Organizational Users)	Vendor and external access paths often create the segmentation exception risk.
Recommendation — Enforce information-flow rules so only approved traffic crosses segment boundaries. Require strong authentication for external and third-party access into sensitive zones.
CIS Controls v8	CIS-12 — Network Infrastructure Management	Segmentation is implemented through disciplined network zoning and control of paths.
Recommendation — Segment networks and tightly govern administrative and remote access routes.
ISO/IEC 27001:2022	A.8.20 — Network security	Network security controls are central to isolating regulated biotech and pharma environments.
Recommendation — Define and enforce secure network zones and boundary controls for critical assets.
OWASP Non-Human Identity Top 10	NHI-05 — Overprivileged NHI	Service accounts and machine access can defeat segmentation when privileges are too broad.
Recommendation — Reduce non-human privileges so machine-to-machine paths cannot bypass segmentation.

Practitioner Guidance

What to prioritise: Build segmentation around the systems that would cause the greatest operational, regulatory, or intellectual-property impact if they were reached from a compromised endpoint. In biotech and pharma, that usually means research repositories, manufacturing support systems, lab environments, and identity services that can unlock them.

What to verify: Test the design from the attacker’s perspective. A useful check is whether a standard user workstation, a compromised vendor connection, or a low-privilege service account can still reach sensitive functions. If yes, the boundary is not yet doing enough work.

Practitioner takeaway: Effective segmentation is not about perfect isolation, it is about making compromise local, observable, and reversible before it reaches systems that matter most.